Document Type
Article
Publication Date
10-1-2023
Abstract
BACKGROUND: Previous studies demonstrated the efficacy of a rifampicin-based regimen in the treatment of acute staphylococcal periprosthetic joint infections (PJIs) treated with surgical debridement. However, evidence is lacking to support the use of rifampicin in cases where the implant is exchanged during revision.
METHODS: We included all consecutive cases of staphylococcal PJIs treated from January 2013 to December 2018 with revision surgery in this international, retrospective, multicenter observational cohort study. PJI was defined according to the European Bone and Joint Infection Society diagnostic criteria. A relapse or reinfection during follow-up, the need for antibiotic suppressive therapy, the need for implant removal, and PJI-related death were defined as clinical failure. Cases without reimplantation or with follow-upexcluded.
RESULTS: A total of 375 cases were included in the final analysis, including 124 1-stage exchanges (33.1%) and 251 2-stage exchanges (66.9%). Of those, 101 cases failed (26.9%). There was no statistically significant difference in failure of patients receiving rifampicin (22.5%, 42/187) and those not receiving rifampicin (31.4%, 59/188;
CONCLUSIONS: Combination treatment with rifampicin increases treatment success in patients with chronic staphylococcal PJI treated with 2-stage exchange arthroplasty.
Recommended Citation
Kramer, Tobias Siegfried; Soriano, Alex; Tedeschi, Sarah; Chen, Antonia F.; Tattevin, Pierre; Senneville, Eric; Gomez-Junyent, Joan; Birlutiu, Victoria; Petersdorf, Sabine; de Brito, Vicens Diaz; Gonzalez, Ignacio Sancho; Belden, Katherine A.; and Wouthuyzen-Bakker, Marjan, "Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study" (2023). Division of Infectious Diseases and Environmental Medicine Faculty Papers. Paper 16.
https://jdc.jefferson.edu/didem/16
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Language
English
Comments
This article is the author’s final published version in Open Forum Infectious Diseases, Volume 10, Issue 10, October 2023, Article number ofad491.
The published version is available at https://doi.org/10.1093/ofid/ofad491. Copyright © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Note
Correction made to this article in Open Forum Infectious Diseases, Volume 11, Issue 3, 2024, Article number ofae075.
The published version is available at https://doi.org/10.1093/ofid/ofae075. Copyright © The Author(s) 2024.